Gabapentin
Product Images NDC 68788-6461

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-6461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 1

The given text represents a formula to calculate the estimated glomerular filtration rate (eGFR) using the Cockcroft-Gault equation. This equation requires two variables - age in years and weight in kilograms, and the serum creatinine level in milligrams per deciliter (mg/dL). The eGFR is calculated in milliliters per minute per 1.73 m² (mL/min/1.73 m²) and is an important measure used to evaluate kidney function. The formula is applicable to both men and women, but different constants are used for the calculation of body weight.*

FDA Label Image

Gabapentin 10

FDA Label Image

Gabapentin 13

This is a product description for Gabapentin capsules, with each capsule containing 100mg Gabapentin. It is a generic version of Neurontin. The package size and expiry date are not available. The manufacturer is Actavis Pharma Inc. The text includes various stock keeping unit (SKU) numbers and codes for product identification. The text also notes that it is prohibited by federal law to transfer this drug to any person other than the patient it was prescribed for. Overall, this is a standard pharmaceutical product description.*

FDA Label Image

Gabapentin 2

FDA Label Image

Gabapentin 3

FDA Label Image

Gabapentin 4

FDA Label Image

Gabapentin 5

FDA Label Image

Gabapentin 6

The text describes a chart or graph showing the mean pain score for a study that involved a dose titration period followed by a fixed dose period of four weeks. The study compared the effectiveness of a placebo to a high dose of gabapentin (3600 mg/day) in reducing pain. The chart shows that the mean pain score decreased substantially more with the gabapentin than with the placebo. Baseline data was collected and the study lasted several weeks.*

FDA Label Image

Gabapentin 7

This appears to be a table displaying mean pain scores and the dosage of Gabapentin used in a study over the course of 4 weeks. The table consists of three columns labeled "Weeks", "< 3%neck Dose Titration Period >", and "4 Week Fixed Dose Period". The rows display mean pain scores for different dosages of Gabapentin, including 0, 1800 mg/day, and 2400 mg/day. Overall, the table seems to be outlining the effect of Gabapentin on pain over a 4-week period.*

FDA Label Image

Gabapentin 8

FDA Label Image

Gabapentin 9

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.